ClinicalTrials.gg
RecruitingNCT05721781PIE-BUpdated Jul 24, 2026

Reducing Risk for Infective Endocarditis

An interventional study of Oral Hygiene instruction and Dental Cleaning in Bacteremia and Infective Endocarditis, sponsored by Wake Forest University Health Sciences. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial is studying if bacteria found in a participant's bloodstream after brushing their teeth can be prevented with a dental cleaning and more education on how to best brush and care for their teeth. One group of participants will have a dental cleaning and oral health instructions and the other group of participants will not. Researchers will compare the blood test results from the two groups to see if the education made a difference in preventing bacteria and how long it stays in the bloodstream.

Read the detailed description

This multi-center randomized clinical trial will determine if an intervention to improve oral hygiene and reduce gingival inflammation decreases the incidence and duration of bacteremia of Infective Endocarditis (IE) causing bacterial species, which may refocus longstanding guidelines on prevention for all people at risk for Infective Endocarditis (IE). The Standardized Brushing Hygienist will brush the participant's teeth over a 2-minute period, during and after which there will be 4 additional blood samples. The participant will then be randomized to an intervention or routine care group. The intervention will consist of a single session of tooth scaling and polishing, and oral hygiene instruction provided at the end of the Randomization Visit. Both groups will return for 3-week and 15-week visits, during which they will undergo a non-invasive oral examination and the brushing procedure with 5 blood samples (baseline and 4 additional blood samples after brushing begins). All blood samples will be cultured for bacteria of IE causing species.

02

Conditions studied

  • Bacteremia
  • Infective Endocarditis

Keywords

  • Oral Hygiene
  • Oral Bacteria
  • Gingival inflammation
03

In context

Bacteremia

297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.

This study's planned enrollment of 320 is above the median of 156 across 156 interventional studies indexed under Bacteremia.

Browse Bacteremia studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,351 studies on the registry; 201 are open to participants now.

Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Greater than 6 months since last dental hygiene prophylaxis (cleaning).
  • 10 or more accessible teeth (including implants, with a minimum of 8 natural teeth).
  • Willing and able to provide .
  • Willing to comply with all study procedures and be available for the duration of the study.
  • Willing to forgo routine professional dental cleanings while enrolled in the trial.

Exclusion criteria

Exclusion Criteria:

  • At high risk for IE, as defined by the 2007/2021 AHA Guidelines:
  • Prosthetic cardiac valve or prosthetic material used for cardiac valve repair.
  • Previous episode of IE.
  • Cardiac transplantation recipient with cardiac valvulopathy.
  • Specific congenital heart disease conditions.
  • Pregnant, by self-report, or planning to become pregnant during the study period.
  • Affected by a condition that, in the opinion of the investigator, may preclude them from study completion or put them at increased risk such as :
  • Hemodialysis dependent.
  • Have a long-term intravascular catheter (e.g., for chemotherapy or parenteral nutrition).
  • Active injection drug use (IDU).
  • Clotting disorder such as, hemophilia.
  • Have a solid organ transplant or hematopoietic stem cell transplant, or ongoing treatment for hematologic cancer.
  • Currently incarcerated.
  • Systemic antibiotic use within the past 2 weeks.
  • Undergoing orthodontic treatment with fixed appliances (brackets and wires) or plans to do so during the study period.
  • Taking or requiring antibiotic prophylaxis prior to dental procedures for other reasons, e.g., to prevent prosthetic joint infection .
  • Three or more teeth with moderate to severe gingival hyperplasia.
  • Has clinically detectable emergent or urgent dental needs that, in the trained and calibrated Oral Examiner's opinion, would require definitive dental care during the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Participants receiving a dental cleaning and oral hygiene instruction

    Participants randomized to this arm will receive a standard dental cleaning and education on proper toothbrushing and flossing technique and asked to follow these toothbrushing and flossing techniques for the duration of the study period. They will receive periodic phone call reminders to maintain these practices during the study period.

    Behavioral: Oral Hygiene instruction · Procedure: Dental Cleaning

  • No intervention
    Control

    Participants randomized to this arm will be instructed to continue with their usual oral hygiene practices for the duration of the study period.

Interventions

  • BehavioralOral Hygiene instruction

    Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).

  • ProcedureDental Cleaning

    Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.

06

What researchers measure

Primary outcomes

  1. Incidence of bacteremia

    Blood samples are assessed for positivity of Infective Endocarditis (IE) causing oral species. A participant is defined as having bacteremia at a visit if that participant has at least one blood draw positive for bacteremia of IE-causing species during or after tooth brushing, provided that those IE-causing species were not present at the pre-brushing blood draw.

    Time frame: Baseline

  2. Incidence of bacteremia

    Blood samples are assessed for positivity of Infective Endocarditis (IE) causing oral species. A participant is defined as having bacteremia at a visit if that participant has at least one blood draw positive for bacteremia of IE-causing species during or after tooth brushing, provided that those IE-causing species were not present at the pre-brushing blood draw.

    Time frame: Week 15

Secondary outcomes

  1. Change in Incidence of bacteremia

    Blood samples are assessed for positivity of Infective Endocarditis (IE) causing oral species. A participant is defined as having bacteremia at a visit if that participant has at least one blood draw positive for bacteremia of IE-causing species during or after tooth brushing, provided that those IE-causing species were not present at the pre-brushing blood draw.

    Time frame: Baseline to Week 3

  2. Change in duration of bacteremia score

    At each visit, participants will have 5 blood samples drawn over the course of \~15 minutes. When a bacteremia occurs at a visit, its duration is defined as the last blood draw that tests positive for an IE-causing bacterial species that was not present at the pre-brushing draw. Possible values for duration are: 0 (no positive blood samples), 1 (only the blood draw during tooth brushing was positive), 2, 3, or 4, where the latter refer respectively to the subsequent blood samples.

    Time frame: Baseline, Week 3, and Week 15

  3. Change in calculus index scores

    The calculus index, defined as the average calculus score (0 to 3 scale) from 4 sites per tooth on all teeth in the dentition, will be measured at each visit - Calculus will be assessed using the index of Ramfjord - 0 = absence of signs of inflammation; 1 = mild to moderate inflammatory gingival changes, not extending around the tooth; 2 = mild to moderately severe gingivitis extending all around the tooth; 3 = severe gingivitis characterized by- marked redness, swelling, tendency to bleed and ulceration - higher scores denote worse changes

    Time frame: Baseline, Week 3, and Week 15

  4. Change in visible plaque scores

    The visible plaque score, defined as the percentage of surfaces with visible plaque across all teeth in the dentition, will be measured at each visit - Marginal dental plaque will be scored as visible or not visible using the criteria of Silness and Lӧe (1964) - Visible plaque corresponds to Silness and Lӧe scores of 2 and 3 - higher scores denote worse plaque

    Time frame: Baseline, Week 3, and Week 15

  5. Change in gingival index scores

    The gingival index, defined as the average gingival score (0 to 3 scale) from 4 sites per tooth on all teeth in the dentition, will be measured at each visit - Gingivitis will be assessed using the Gingival Index of Lӧe and Silness - A score from 0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation from, and 2.1-3.0 signifies severe inflammation - higher scores denote increased inflammation

    Time frame: Baseline, Week 3, and Week 15

07

Study locations

3 of 6 sites recruiting
  • Tufts University School of Dental Medicine and Tufts University Health Sciences Campus
    Boston, Massachusetts 02111, United States
    Withdrawn

    Not enrolling at this site.

  • University of Michigan School of Dentistry and Michigan Medicine
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Rutgers School of Dental Medicine
    Newark, New Jersey 07103, United States
    Recruiting
  • New York University
    New York, New York 10010, United States
    Not yet recruiting
    • Leticia Arbex · Contactla1669@nyu.edu · 212-998-9800
    • Mariana Bucovsky · Contactmb10357@nyu.edu
    • R. Alexander Kerr · Principal investigator
  • University of Rochester Medical Center
    Rochester, New York 14620, United States
    Completed

    Not enrolling at this site.

  • Atrium Health's Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — A public use dataset will be available upon study completion.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05721781
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Aug 31, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 24, 2026

Study contacts

Cathy Petersen, RDH
Contact
cathleen.petersen@atriumhealth.org
704-355-1494
Kate Sullivan, MA
Contact
kathleen.sullivan@atriumhealth.org
704-355-9496
Peter Lockhart, DDS
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion